Last reviewed · How we verify
Flupenthixol — Competitive Intelligence Brief
phase 2
D(1B) dopamine receptor, D(4) dopamine receptor, Solute carrier family 22 member 1
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Flupenthixol (Flupenthixol) — National Institute on Drug Abuse (NIDA).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Flupenthixol TARGET | Flupenthixol | National Institute on Drug Abuse (NIDA) | phase 2 | D(1B) dopamine receptor, D(4) dopamine receptor, Solute carrier family 22 member 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Flupenthixol CI watch — RSS
- Flupenthixol CI watch — Atom
- Flupenthixol CI watch — JSON
- Flupenthixol alone — RSS
Cite this brief
Drug Landscape (2026). Flupenthixol — Competitive Intelligence Brief. https://druglandscape.com/ci/flupenthixol. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing